Avenue Therapeutics Inc.

0.3129-0.0250-7.40%Vol 65.70K1Y Perf -92.23%
May 18th, 2022 16:00 DELAYED
BID0.3101 ASK0.3399
Open0.3500 Previous Close0.3379
Pre-Market- After-Market0.31
 - -  - -%
Target Price
9.00 
Analyst Rating
— 0.00
Potential %
2.78K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.26 
Earnings Rating
Neutral
Market Cap6.80M 
Earnings Date
5th Jan 2022
Alpha-0.03 Standard Deviation0.25
Beta1.04 

Today's Price Range

0.31260.3500

52W Range

0.20005.19

5 Year PE Ratio Range

-9.50-3.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
6.26%
1 Month
-28.62%
3 Months
28.48%
6 Months
-73.18%
1 Year
-92.23%
3 Years
-92.81%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATXI0.3129-0.0250-7.40
AAPL140.82-8.4200-5.64
GOOG2 248.02-86.0100-3.69
MSFT254.08-12.1200-4.55
XOM90.65-1.4600-1.59
WFC42.11-1.6000-3.66
JNJ175.50-3.3200-1.86
FB192.24-10.3800-5.12
GE75.20-1.2000-1.57
JPM120.09-2.0900-1.71
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.10-0.0640.00
Q02 2020-0.10-0.11-10.00
Q01 2020-0.17-0.0852.94
Q04 2019--0.32-
Q03 2019-0.32-0.1456.25
Q02 2019-0.57-0.4324.56
Q01 2019-0.44-0.82-86.36
Q04 2018-0.47-0.3819.15
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.050.00-
12/2021 QR-0.0420.00Positive
12/2021 FY-0.20-300.00Negative
12/2022 FY-0.1814.29Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume65.70K
Shares Outstanding21.73K
Shares Float11.59M
Trades Count211
Dollar Volume22.23K
Avg. Volume1.82M
Avg. Weekly Volume160.65K
Avg. Monthly Volume271.05K
Avg. Quarterly Volume5.02M

Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 0.3379 per share at the end of the most recent trading day (a 1.75% change compared to the prior day closing price) with a volume of 141.53K shares and market capitalization of 6.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Lucy Lu.

The one-year performance of Avenue Therapeutics Inc. stock is -92.23%, while year-to-date (YTD) performance is -62.79%. ATXI stock has a five-year performance of %. Its 52-week range is between 0.2 and 5.185, which gives ATXI stock a 52-week price range ratio of 2.26%

Avenue Therapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 2.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -106.89%, a ROC of -128.67% and a ROE of -132.14%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Avenue Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is (0), with a target price of $9, which is +2 776.32% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.54, ATR14 : 0.05, CCI20 : -59.99, Chaikin Money Flow : -0.12, MACD : -0.05, Money Flow Index : 32.36, ROC : -8.60, RSI : 37.67, STOCH (14,3) : 56.23, STOCH RSI : 1.00, UO : 53.51, Williams %R : -43.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were: Joseph Vazzano (Sold 7 160 shares of value $11 599 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Hold
3.00

Avenue Therapeutics Inc.

Avenue Therapeutics Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of postoperative pain.

CEO: Lucy Lu

Telephone: +1 781 652-4500

Address: 1140 Avenue of the Americas, New York 10036, NY, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

82%18%

Bearish Bullish

63%38%

Bearish Bullish

64%36%

News

Stocktwits